Alliancebernstein L.P. Has $61.27 Million Position in Ascendis Pharma A/S (NASDAQ:ASND)

Alliancebernstein L.P. cut its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 2.1% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 445,028 shares of the biotechnology company’s stock after selling 9,760 shares during the period. Alliancebernstein L.P.’s holdings in Ascendis Pharma A/S were worth $61,267,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of ASND. Rice Hall James & Associates LLC boosted its position in Ascendis Pharma A/S by 2.0% during the fourth quarter. Rice Hall James & Associates LLC now owns 163,888 shares of the biotechnology company’s stock valued at $22,562,000 after purchasing an additional 3,274 shares during the last quarter. Nomura Asset Management Co. Ltd. raised its stake in shares of Ascendis Pharma A/S by 42.5% during the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 18,000 shares of the biotechnology company’s stock worth $2,688,000 after purchasing an additional 5,371 shares in the last quarter. Exome Asset Management LLC boosted its holdings in shares of Ascendis Pharma A/S by 119.2% in the 3rd quarter. Exome Asset Management LLC now owns 43,849 shares of the biotechnology company’s stock valued at $6,547,000 after buying an additional 23,849 shares during the last quarter. abrdn plc grew its stake in shares of Ascendis Pharma A/S by 18.3% in the fourth quarter. abrdn plc now owns 187,180 shares of the biotechnology company’s stock valued at $25,769,000 after buying an additional 28,967 shares in the last quarter. Finally, GAMMA Investing LLC increased its holdings in Ascendis Pharma A/S by 58.0% during the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock worth $80,000 after buying an additional 214 shares during the last quarter.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Cantor Fitzgerald lifted their price objective on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an “overweight” rating in a research report on Tuesday, February 25th. JPMorgan Chase & Co. lifted their price target on Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an “overweight” rating in a report on Tuesday, March 18th. Morgan Stanley set a $180.00 price objective on Ascendis Pharma A/S in a research note on Tuesday, February 18th. The Goldman Sachs Group lifted their target price on Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. Finally, Evercore ISI boosted their target price on Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an “outperform” rating in a report on Tuesday, February 18th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $204.64.

Ascendis Pharma A/S Stock Down 4.9 %

Shares of Ascendis Pharma A/S stock opened at $142.67 on Friday. The company has a 50-day simple moving average of $146.39 and a two-hundred day simple moving average of $138.07. Ascendis Pharma A/S has a twelve month low of $111.09 and a twelve month high of $169.37. The stock has a market capitalization of $8.66 billion, a price-to-earnings ratio of -20.09 and a beta of 0.61.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.32) by $0.64. On average, sell-side analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.